ADVERTISEMENT
Search

 

Press Releases

 

3

Nov

2022

New interactive map promotes access to pharmacy services

Author: Anonym

Dima M. Qato, PharmD, MPH, PhD, regards pharmacy access as a human rights issue. Qato, an associate professor at the School of Pharmacy at the University of Southern California (USC) and a senior fellow at the USC Leonard D. Schaeffer Center for Health Policy & Economics, developed an interactive, nationwide mapping tool that reveals the presence of “pharmacy deserts” around the country.

Comments (0)
Number of views (17841)
Article rating: 5.0
Read more

Categories: APhA News

Tags: APhA News

3

Nov

2022

One in ten older adults in the U.S. has dementia, study suggests

Author: Anonym

A study published in JAMA Neurology estimated that in the United States, 1 in 10 adults over the age of 65 has dementia and 1 in 5 has cognitive difficulties.

Comments (0)
Number of views (22255)
Article rating: 5.0
Read more

Categories: APhA News

Tags: APhA News

3

Nov

2022

FDA releases draft guidance to spur development of CDI drugs

Author: Anonym

New guidance released by FDA provides advice for sponsors on developing drugs for treating Clostridioides difficile infection (CDI). The draft guidance discusses how to design trials and trial populations, efficacy and safety endpoints, nonclinical studies, and pharmacokinetic studies.

Comments (0)
Number of views (15450)
Article rating: No rating
Read more

Categories: APhA News

Tags: APhA News

31

Oct

2022

ACIP votes on new pneumococcal vaccine for those who got PCV13

Author: Anonym

New recommendations put forth from ACIP last week addressed the use of the 20-valent conjugate pneumococcal vaccine (PCV20, also called Prevnar 20) in adults with a vaccine history that includes the 13-valent conjugate vaccine (PCV13, also known as Prevnar 13).

Comments (0)
Number of views (17685)
Article rating: 3.5
Read more

Categories: APhA News

Tags: APhA News

27

Oct

2022

Researchers continue to study effectiveness of ivermectin for COVID-19

Author: Anonym

Researchers wanted to find out if ivermectin compared to placebo shortened symptom duration for adult patients in the United States with symptomatic mild to moderate COVID-19. According to results of the randomized clinical trial published in JAMA on October 21, 2022, the research team found that among outpatients with mild to moderate COVID-19, treatment with ivermectin compared with placebo did not significantly improve time to recovery

Comments (0)
Number of views (17274)
Article rating: 4.4
Read more

Categories: APhA News

Tags: APhA News

RSS
First2930313234363738Last
Advertisement
Advertisement
Advertisement
Advertisement
ADVERTISEMENT